Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Sep 27. doi: 10.1007/s00115-018-0607-0. [Epub ahead of print] Review. German.

PMID:
30264269
2.

Flaccid paralysis in neuromyelitis optica: An atypical presentation with possible involvement of the peripheral nervous system.

Grüter T, Ayzenberg I, Gahlen A, Kneiphof J, Gold R, Kleiter I.

Mult Scler Relat Disord. 2018 Jul 20;25:83-86. doi: 10.1016/j.msard.2018.07.032. [Epub ahead of print]

PMID:
30056360
3.

Mobile Palliative Care Consultation Service (PCCS): Overview of Hospice and Palliative Care Evaluation (HOPE) Data on In-Patients With End-Stage Cancer, Multiple Sclerosis, and Noncancer, Nonneurological Disease From 4 PCCS Centers in Germany in 2013.

Basedow-Rajwich B, Montag T, Duckert A, Schulz C, Rajwich G, Kleiter I, Koehler J, Lindena G.

Palliat Care. 2018 Jul 18;11:1178224218785139. doi: 10.1177/1178224218785139. eCollection 2018.

4.

Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis.

Köpke S, Giordano A, Veronese S, Christin Rahn A, Kleiter I, Basedow-Rajwich B, Fornari A, Battaglia MA, Drulovic J, Kooij L, Koops J, Mens J, Meza Murillo ER, Milanov I, Milo R, Patti F, Pekmezovic T, Sastre-Garriga J, Vosburgh J, Voltz R, Bay J, Oliver DJ, Solari A.

Eur J Neurol. 2018 Jul 23. doi: 10.1111/ene.13760. [Epub ahead of print]

PMID:
30035845
5.

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder.

Thöne J, Lichtenberg S, Stahl A, Pache F, Kleiter I, Ruprecht K, Gold R, Hellwig K.

Front Neurol. 2018 Jun 19;9:446. doi: 10.3389/fneur.2018.00446. eCollection 2018.

6.

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.

Wilmes AT, Reinehr S, Kühn S, Pedreiturria X, Petrikowski L, Faissner S, Ayzenberg I, Stute G, Gold R, Dick HB, Kleiter I, Joachim SC.

J Neuroinflammation. 2018 Jun 14;15(1):183. doi: 10.1186/s12974-018-1208-3.

7.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

8.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
9.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

10.

Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) - Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation.

Rahn AC, Köpke S, Backhus I, Kasper J, Anger K, Untiedt B, Alegiani A, Kleiter I, Mühlhauser I, Heesen C.

Int J Nurs Stud. 2018 Feb;78:26-36. doi: 10.1016/j.ijnurstu.2017.08.011. Epub 2017 Aug 26.

PMID:
28982479
11.

Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

Kleiter I, Lang M, Jeske J, Norenberg C, Stollfuß B, Schürks M.

BMC Neurol. 2017 Sep 6;17(1):174. doi: 10.1186/s12883-017-0953-8.

12.

Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample.

Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth SG, Köpke S, Heesen C.

Patient Educ Couns. 2018 Jan;101(1):74-78. doi: 10.1016/j.pec.2017.07.018. Epub 2017 Jul 17.

PMID:
28764895
13.

[Early onset of fingolimod-associated macular edema].

Schelenz D, Kleiter I, Schöllhammer J, Rehrmann J, Elling M, Dick HB, Kakkassery V.

Ophthalmologe. 2018 May;115(5):424-428. doi: 10.1007/s00347-017-0526-7. German.

PMID:
28653209
14.

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363. eCollection 2017 Jul.

15.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

16.

Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis.

Popkirov S, Ayzenberg I, Hahn S, Bauer J, Denno Y, Rieckhoff N, Radzimski C, Hans VH, Berg S, Roghmann F, Noldus J, Bien CG, Skodda S, Wellmer J, Stöcker W, Krogias C, Gold R, Schlegel U, Probst C, Komorowski L, Miske R, Kleiter I.

Acta Neuropathol Commun. 2017 May 29;5(1):40. doi: 10.1186/s40478-017-0447-3.

17.

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W.

J Neurol Sci. 2017 May 15;376:181-190. doi: 10.1016/j.jns.2017.03.001. Epub 2017 Mar 7.

PMID:
28431609
18.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.

PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.

19.

SMAD7 deficiency stimulates Müller progenitor cell proliferation during the development of the mammalian retina.

Kugler M, Schlecht A, Fuchshofer R, Schmitt SI, Kleiter I, Aigner L, Tamm ER, Braunger BM.

Histochem Cell Biol. 2017 Jul;148(1):21-32. doi: 10.1007/s00418-017-1549-5. Epub 2017 Mar 3.

PMID:
28258388
20.

TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity.

Lukas D, Yogev N, Kel JM, Regen T, Mufazalov IA, Tang Y, Wanke F, Reizis B, Müller W, Kurschus FC, Prinz M, Kleiter I, Clausen BE, Waisman A.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1480-E1489. doi: 10.1073/pnas.1615065114. Epub 2017 Feb 6.

21.

Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice.

Feng T, Dzieran J, Yuan X, Dropmann A, Maass T, Teufel A, Marhenke S, Gaiser T, Rückert F, Kleiter I, Kanzler S, Ebert MP, Vogel A, Ten Dijke P, Dooley S, Meindl-Beinker NM.

Oncogenesis. 2017 Jan 30;6(1):e294. doi: 10.1038/oncsis.2016.85.

22.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):281.

23.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 27;13(1):280.

24.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 26;13(1):279.

25.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
26.

Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.

Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e285. eCollection 2016 Dec. No abstract available.

27.

Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis.

Horstmann L, Kuehn S, Pedreiturria X, Haak K, Pfarrer C, Dick HB, Kleiter I, Joachim SC.

J Neuroimmunol. 2016 Sep 15;298:32-41. doi: 10.1016/j.jneuroim.2016.06.008. Epub 2016 Jun 23.

PMID:
27609273
28.

Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.

Hoepner R, Kolb EM, Dahlhaus S, Hellwig K, Adams O, Kleiter I, Salmen A, Schneider R, Lukas C, Chan A, Berger JR, Gold R.

Mult Scler. 2017 May;23(6):830-835. doi: 10.1177/1352458516667241. Epub 2016 Sep 6.

PMID:
27600113
29.

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I.

JAMA Neurol. 2016 Oct 1;73(10):1251-1253. doi: 10.1001/jamaneurol.2016.2588. No abstract available.

PMID:
27533122
30.

Autonomic and peripheral nervous system function in acute tick-borne encephalitis.

Neumann B, Schulte-Mattler W, Brix S, Pöschl P, Jilg W, Bogdahn U, Steinbrecher A, Kleiter I.

Brain Behav. 2016 May 5;6(8):e00485. doi: 10.1002/brb3.485. eCollection 2016 Aug.

31.

Cervical cord and ventricle affection in neuromyelitis optica.

Schneider R, Bellenberg B, Kleiter I, Gold R, Köster O, Weiler F, Hahn H, Lukas C.

Acta Neurol Scand. 2017 Mar;135(3):324-331. doi: 10.1111/ane.12601. Epub 2016 Apr 21.

PMID:
27098675
32.

Tocilizumab, MS, and NMOSD.

Kleiter I, Ayzenberg I, Araki M, Yamamura T, Gold R.

Mult Scler. 2016 Dec;22(14):1891-1892. Epub 2016 Apr 11. No abstract available.

PMID:
27068554
33.

Relevance of endoglin, IL-1α, IL-1β and anti-ovarian antibodies in females with multiple sclerosis.

Thöne J, Kleiter I, Stahl A, Ellrichmann G, Gold R, Hellwig K.

J Neurol Sci. 2016 Mar 15;362:240-3. doi: 10.1016/j.jns.2016.01.057. Epub 2016 Jan 28.

PMID:
26944156
34.

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Ayzenberg I, Hoepner R, Kleiter I.

Ther Clin Risk Manag. 2016 Feb 19;12:261-72. doi: 10.2147/TCRM.S65558. eCollection 2016. Review.

35.

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.

Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, Pache F, Obermann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter I; Neuromyelitis Optica Study Group.

J Neurol. 2016 Mar;263(3):575-82. doi: 10.1007/s00415-015-7991-1. Epub 2016 Jan 25.

PMID:
26810718
36.

Enhanced OCT4 transcriptional activity substitutes for exogenous SOX2 in cellular reprogramming.

Marthaler AG, Adachi K, Tiemann U, Wu G, Sabour D, Velychko S, Kleiter I, Schöler HR, Tapia N.

Sci Rep. 2016 Jan 14;6:19415. doi: 10.1038/srep19415.

37.

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Kleiter I, Gold R.

Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Review.

38.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

PMID:
26537743
39.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.

J Neurol. 2016 Jan;263(1):140-9. doi: 10.1007/s00415-015-7952-8. Epub 2015 Nov 3.

40.

Retinal Involvement in a Patient with Cerebral Manifestation of Chronic Graft-Versus-Host-Disease.

Blecha C, Angstwurm K, Wolff D, Holler E, Helbig H, Grassinger J, Rennert J, Kleiter I, Huber E, Schmid C, Dietrich-Ntoukas T.

Oncol Res Treat. 2015;38(10):532-4. doi: 10.1159/000439490. Epub 2015 Sep 11.

PMID:
26452109
41.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

42.

Heterozygous modulation of TGF-β signaling does not influence Müller glia cell reactivity or proliferation following NMDA-induced damage.

Kugler M, Schlecht A, Fuchshofer R, Kleiter I, Aigner L, Tamm ER, Braunger BM.

Histochem Cell Biol. 2015 Nov;144(5):443-55. doi: 10.1007/s00418-015-1354-y. Epub 2015 Jul 28.

PMID:
26215132
43.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K.

JAMA Neurol. 2015 Jul;72(7):815-22. doi: 10.1001/jamaneurol.2015.0248. Review.

44.

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I.

JAMA Neurol. 2015 Jul;72(7):756-63. doi: 10.1001/jamaneurol.2015.0533.

PMID:
25985228
45.

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.

Krumbholz M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, Aktas O, Buchholz G, Kern P, Straube A, Kümpfel T.

J Neurol. 2015 May;262(5):1379-84. doi: 10.1007/s00415-015-7766-8. Epub 2015 May 10.

46.

Demographic and clinical features of neuromyelitis optica: A review.

Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica.

Mult Scler. 2015 Jun;21(7):845-53. doi: 10.1177/1352458515572406. Epub 2015 Apr 28. Review.

47.

Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation.

Hasan M, Neumann B, Haupeltshofer S, Stahlke S, Fantini MC, Angstwurm K, Bogdahn U, Kleiter I.

Immunol Cell Biol. 2015 Aug;93(7):662-72. doi: 10.1038/icb.2015.21. Epub 2015 Mar 31.

PMID:
25823994
48.

Analysis of neurogenesis during experimental autoimmune encephalomyelitis reveals pitfalls of bioluminescence imaging.

Ayzenberg I, Schlevogt S, Metzdorf J, Stahlke S, Pedreitturia X, Hunfeld A, Couillard-Despres S, Kleiter I.

PLoS One. 2015 Mar 17;10(3):e0118550. doi: 10.1371/journal.pone.0118550. eCollection 2015.

49.

Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis.

Thöne J, Kollar S, Nousome D, Ellrichmann G, Kleiter I, Gold R, Hellwig K.

Mult Scler. 2015 Jan;21(1):41-7. doi: 10.1177/1352458514540843. Epub 2014 Aug 21.

PMID:
25145691
50.

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.

Jarius S, Paul F, Fechner K, Ruprecht K, Kleiter I, Franciotta D, Ringelstein M, Pache F, Aktas O, Wildemann B.

J Neuroinflammation. 2014 Jul 29;11:129. doi: 10.1186/1742-2094-11-129.

Supplemental Content

Loading ...
Support Center